This is a Validated Antibody Database (VAD) review about mouse Sema7a, based on 4 published articles (read how Labome selects the articles), using Sema7a antibody in all methods. It is aimed to help Labome visitors find the most suited Sema7a antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Sema7a synonym: 2900057C09Rik; CDw108; H-Sema-L; M-Sema-L; Semal; semaphorin-7A; H-Sema K1; Semaphorin K1; sema K1; sema L; semaphorin-K1; semaphorin-L
Knockout validation
R&D Systems goat polyclonal |
| R&D Systems Sema7a antibody (R&D Systems, AF1835) was used in western blot knockout validation on mouse samples at 1:1000 (fig s1h). Nat Commun (2017) ncbi |
R&D Systems
goat polyclonal |
| R&D Systems Sema7a antibody (R&D Systems, AF1835) was used in western blot knockout validation on mouse samples at 1:1000 (fig s1h). Nat Commun (2017) ncbi |
rat monoclonal (238906) |
| In order to characterize corneal nerve network alterations induced by HSV-1 infection, R&D Systems Sema7a antibody (R&D Systems, MAB2068) was used in blocking or activating experiments on mouse samples . Invest Ophthalmol Vis Sci (2015) ncbi |
goat polyclonal |
| R&D Systems Sema7a antibody (R&D System, AF1835) was used in western blot on mouse samples at 1:1000. Mol Immunol (2013) ncbi |
Abcam
rabbit polyclonal |
| Abcam Sema7a antibody (abcam, ab23578) was used in immunocytochemistry on human samples (fig 1) and in western blot on human samples (fig 1). PLoS ONE (2016) ncbi |
rabbit polyclonal |
| In order to characterize corneal nerve network alterations induced by HSV-1 infection, Abcam Sema7a antibody (Abcam, ab23578) was used in western blot on mouse samples at 1:200. Invest Ophthalmol Vis Sci (2015) ncbi |
Articles Reviewed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments